Loading...

NEXTGEN HRR 29 GENE PANEL ( SOMATIC)

image not found

NABL Cap Accredited 
The NextGen HRR 29 Gene Panel (Somatic) at Metropolis Healthcare is a focused tumor-profiling assay designed to detect acquired (somatic) mutations in 29 genes involved in Homologous Recombination Repair (HRR). These mutations help guide the use of targeted therapies such as PARP inhibitors and support personalized cancer treatment decisions. Metropolis Healthcare uses high-depth Next-Generation Sequencing to ensure accurate detection of clinically relevant variants. This test is ideal for patients with solid tumors requiring precise molecular insights for therapy optimization.
 

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 27,000.00

Sample Type: Tissue

Fasting Not Required


Notes:N8222

Frequently Asked Questions (FAQ's):

What does the HRR 29 Gene Panel (Somatic) at Metropolis Healthcare include?
It evaluates 29 HRR-related genes for tumor-acquired mutations that influence targeted therapy selection.

How does Metropolis Healthcare perform this somatic gene panel?
Metropolis Healthcare conducts high-depth NGS on tumor tissue using validated workflows and advanced bioinformatics.

Who should consider this test at Metropolis Healthcare?
Patients with solid tumors, especially ovarian, breast, pancreatic, or prostate cancers, should consider it for therapy planning.

Is fasting required for this somatic genetic test at Metropolis Healthcare?
No fasting is required; the test is performed on tumor tissue samples.

How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to detailed tumor sequencing and interpretation.

Can this test at Metropolis Healthcare help guide targeted treatments?
Yes, HRR mutations can indicate suitability for PARP inhibitors and other precision therapies.

How accurate is the somatic mutation analysis at Metropolis Healthcare?
Metropolis Healthcare ensures high analytical accuracy through deep sequencing coverage and stringent QC checks.

Does this test support personalized cancer management at Metropolis Healthcare?
Yes, it provides actionable insights that help clinicians tailor treatment strategies for improved outcomes.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab